Browse categories and answer follow-up questions to refine your symptom profile.
Approach to the Critical Patient
Immediate priorities
Airway and breathing threats
Fulminant inhalational anthrax
Rapid progression from flu-like prodrome to respiratory failure within hours
Biphasic course with brief improvement before collapse
Oxygenation failure
SpO2 < 90% on room air
PaO2 < 60 mmHg from large pleural effusions
Airway edema from injection or head and neck cutaneous disease
Massive soft tissue edema
If expanding airway edema, early definitive airway control
If respiratory failure, rapid sequence intubation preparation
Lung protective ventilation
Pleural drainage before or alongside intubation
Circulation and toxemia threats
Anthrax toxin mediated shock
Lethal toxin and edema toxin driven vascular collapse
Shock may persist after bacterial sterilization
Shock physiology
SBP < 90 mmHg
MAP < 65 mmHg
Lactate >= 2 mmol/l
If septic shock, antibiotics and antitoxin within 1 hour
Triple antimicrobial therapy
Adjunctive antitoxin for systemic disease
Neurologic and hemorrhagic threats
Hemorrhagic meningitis
Occurs in up to 50% of systemic cases
Altered mental status and seizures
Coagulopathy
Present in about one third of systemic cases
Bleeding risk with procedures
If altered mental status, lumbar puncture and CNS active regimen
Meropenem for CNS penetration
Assume meningitis until ruled out
Early recognition and decision points
Pathognomonic red flags
Widened mediastinum on chest radiograph in a febrile patient
Essentially diagnostic of advanced inhalational anthrax
Hemorrhagic mediastinal lymphadenopathy on CT
Painless black eschar with disproportionate edema
Cutaneous form
Surrounding non-pitting edema
Clustering of patients with similar respiratory illness
Suggests intentional aerosol release
Suspicious powder or mail exposure
Form based branching
Cutaneous localized vs systemic
Localized lesion without systemic signs
Systemic signs trigger IV therapy and admission
Inhalational, ingestion, injection
All systemic forms require ICU level care
Meningitis complicates any form
Team activation and public health
Immediate notifications
Local and state health department
Anthrax is a nationally notifiable disease
Report any suspected case
CDC and Laboratory Response Network
Confirmatory testing coordination
Medical countermeasure access
Consultation triggers
Infectious disease for all cases
Regimen selection and antitoxin
Duration and step-down planning
Critical care for systemic disease
Vasopressor and ventilator management
Pleural drainage coordination
History
Exposure history
Animal and occupational exposure
Contact with herbivores
Sheep, goats, cattle
Hides, wool, bone meal
Occupational risk groups
Farmers and veterinarians
Wool, hide, and textile workers
Laboratory personnel
Travel and environmental exposure
Endemic regions
Sub-Saharan Africa
Central and southwestern Asia
Southern and eastern Europe
Contaminated meat ingestion
Undercooked meat from infected animals
Injection and bioterrorism exposure
Injection drug use
Heroin contaminated with spores
Suspicious powder or mail
Intentional aerosol release concern
Clustering of similar cases
Form specific presentation
Cutaneous presentation
Painless pruritic papule progression
Papule to vesicle to black eschar
Edema disproportionate to lesion size
Associated systemic features
About one third develop fever
Regional lymphadenopathy
Inhalational presentation
Biphasic course
Flu-like prodrome lasting hours to days
Brief improvement then fulminant collapse
Distinguishing prodrome features
Nonproductive cough
Absence of rhinorrhea
Ingestion and injection presentation
Ingestion features
Nausea, vomiting, bloody diarrhea
Abdominal pain with ascites in over half of cases
Injection features
Severe soft tissue infection at injection site
Marked local edema
Incubation and timeline
Incubation periods
Cutaneous about 1 to 7 days
Lesion evolves over days
Inhalational median 7 days
Interquartile range 4 to 9 days
Can extend up to 6 weeks
Ingestion 1 to 7 days
Injection about 1 day
Risk and comorbidity
Prior vaccination and immune status
Anthrax vaccine adsorbed series status
Partial protection if incomplete
Immunocompromised status
May require extended prophylaxis
Comorbidities worsening outcome
Diabetes and obesity
Associated with severe cutaneous anthrax
Hypertension and COPD
Significantly associated with severe disease
Physical Exam
Vital signs and general
Stability snapshot
Temperature
Fever may be absent early
High fever with systemic disease
Blood pressure
SBP < 90 mmHg as toxemic shock marker
MAP < 65 mmHg
Respiratory parameters
Tachypnea and hypoxia
Signs of respiratory distress
General appearance
Toxic appearing patient
Diaphoresis
Hemodynamic compromise
Mental status
Confusion as meningitis clue
Agitation from hypoxemia
Cutaneous and soft tissue exam
Cutaneous lesion
Painless black eschar
Central necrotic crust
Surrounding vesicles
Disproportionate edema
Non-pitting gelatinous edema
Extends beyond lesion margins
Regional lymphadenopathy
Tender draining nodes
Injection site findings
Severe soft tissue edema and induration
Compartment syndrome risk
Absence of classic eschar in many cases
Systemic organ exam
Respiratory exam
Decreased breath sounds
Pleural effusions in up to 76% of inhalational cases
Dullness to percussion
Signs of respiratory failure
Accessory muscle use
Neurologic exam
Meningismus
Nuchal rigidity
Kernig and Brudzinski signs
Focal and global deficits
Altered mental status
Focal deficits or seizures
Abdominal exam
Ingestion form findings
Tenderness and distension
Ascites
PITFALLS
Diagnostic anchoring errors
Inhalational anthrax mistaken for influenza
Rhinorrhea absent in anthrax
Widened mediastinum distinguishes anthrax
Painless lesion dismissed
Painlessness is a key cutaneous clue
Edema out of proportion
Missed deterioration
Brief prodromal improvement falsely reassuring
Fulminant collapse follows
Reassess frequently
Differential Diagnosis
Cutaneous differentials
Painless eschar mimics
Staphylococcal furuncle
Painful and purulent unlike anthrax
ICD-10 L02 cutaneous abscess
Ecthyma gangrenosum
Pseudomonas in immunocompromised
Necrotic ulcer with halo
Brown recluse spider bite
Painful necrotic ulcer
No disproportionate edema
Orf and tularemia ulceroglandular
Animal exposure overlap
Distinct lesion morphology
Inhalational and mediastinal differentials
Respiratory and mediastinal mimics
Influenza and COVID-19
Rhinorrhea common unlike anthrax
No mediastinal widening
Community acquired pneumonia
Lobar consolidation pattern
ICD-10 J18.9
Tularemia pneumonia
Animal and tick exposure
Late inhalational mimics
Aortic dissection
Mediastinal widening without fever
Tearing chest pain
Acute mediastinitis from histoplasma
Mediastinal lymphadenopathy
Superior vena cava syndrome
Facial plethora and venous distension
Ingestion and meningitis differentials
Acute abdomen mimics
Appendicitis and perforation
Localized peritoneal signs
ICD-10 K35
Mesenteric ischemia
Pain out of proportion
Hemorrhagic meningitis mimics
Bacterial meningitis
CSF shows gram-positive rods in anthrax
ICD-10 G00.8
Subarachnoid hemorrhage
Thunderclap headache
Hemorrhagic CSF overlap
Laboratory Tests
Microbiology
Blood cultures
Most useful diagnostic test
Obtain before antibiotics
Growth in 6 to 24 hours
Antibiotic effect
Even 1 to 2 doses can sterilize cultures
Gram stain
Blood, vesicular fluid, CSF, or tissue
Large encapsulated gram-positive rods
Boxcar shaped morphology
Point-of-care peripheral smear
Bacilli visible in advanced bacteremia
Confirmatory reference testing
PCR targets
pagA, lef, capB
Performed at LRN laboratories
Adjunct confirmatory methods
Immunohistochemistry
Gamma phage lysis
Hematology and chemistry
Complete blood count
Neutrophilic leukocytosis with bandemia
Especially inhalational form
Hemoconcentration
Reflects capillary leak
Coagulation studies
Coagulopathy in about one third of systemic cases
Prolonged PT and PTT
Bleeding risk before procedures
Metabolic and hepatic panel
Elevated transaminases
Reflects systemic toxemia
Renal function and lactate
Lactate >= 2 mmol/l as hypoperfusion marker
Guides antibiotic dosing
CSF and serology
Lumbar puncture
Required to rule out meningitis
Hemorrhagic CSF
PMN pleocytosis with gram-positive rods
Defer if coagulopathy uncorrected
Treat empirically for CNS disease
Serology
Anti-protective antigen ELISA
Useful only retrospectively
Not for acute diagnosis
Diagnostic Tests
Scoring Systems
CDC Anthrax Triage Checklist
Mass exposure triage tool
Distinguishes anthrax from non-anthrax illness
95% sensitivity
Performance characteristics
Correctly classified 95% of anthrax cases
Correctly classified 76% of controls
Sepsis and severity tools
qSOFA
RR >= 22 per minute
SBP <= 100 mmHg
Altered mental status
Form based mortality stratification
Localized cutaneous about 2% treated mortality
Inhalational about 45% in modern era
Meningitis exceeding 90% mortality
MRI
Brain MRI
Hemorrhagic meningitis evaluation
Subarachnoid and subdural hemorrhage
Intraparenchymal hemorrhage
Indications
Altered mental status with systemic anthrax
Seizures or focal deficits
Limitations
Unstable patient constraints
CT often used first for speed
CT
CT chest
Gold standard for inhalational disease
Hyperdense hemorrhagic mediastinal lymphadenopathy on non-contrast CT
Bilateral pleural effusions
Additional findings
Mediastinal fat edema
Pericardial effusion
Contrast considerations
Renal function assessment
Non-contrast detects hemorrhagic nodes
CT brain and abdomen
CT brain
Hemorrhagic meningitis screening
Faster than MRI in unstable patients
CT abdomen
Ascites and bowel wall thickening
Mesenteric lymphadenopathy in ingestion form
Ultrasound
Echocardiography
Pericardial effusion detection
Tamponade physiology screen
Guides drainage decisions
Hemodynamic assessment
LV function in toxemic shock
Volume status estimate
Thoracic and abdominal ultrasound
Pleural effusion assessment
Quantify effusion size
Guide thoracentesis and drainage
Abdominal free fluid
Ascites detection in ingestion form
Guides paracentesis
Disposition
Level of care
ICU admission
All systemic anthrax
Inhalational, ingestion, injection
Cutaneous with systemic signs
Meningitis
Neurologic monitoring
Seizure precautions
Hemodynamic and respiratory support
Vasopressors and ventilation
Pleural drainage access
Floor admission
Cutaneous with concerning features
Extensive edema
Head and neck involvement
Outpatient management
Uncomplicated localized cutaneous anthrax
No systemic signs
Close follow-up arranged
Notification and consultation
Public health notification
Immediate health department contact
Nationally notifiable disease
CDC coordination
Countermeasure access
Outbreak investigation
Specialist involvement
Infectious disease for all cases
Regimen and antitoxin guidance
Surgery for injection anthrax
Prompt debridement may be critical
Neurosurgery for meningitis with mass effect
Surgical decompression consideration
Treatment
Initial stabilization
Systemic disease support
ICU sepsis bundle
Aggressive IV fluid resuscitation
Vasopressors for refractory shock
Prophylaxis measures
DVT prophylaxis
GI bleeding prophylaxis
Mechanical ventilation as needed
Lung protective strategy
Pleural and effusion management
Early aggressive pleural drainage
Recommended for all inhalational cases
Pleural fluid contains high lethal factor concentration
Pericardial drainage
For tamponade physiology
Antimicrobial therapy systemic
Triple therapy for systemic disease or meningitis
Two bactericidal drugs plus a protein synthesis inhibitor
Reduces toxin production
Different drug classes
Ciprofloxacin IV
400 mg IV every 8 hours
Bactericidal fluoroquinolone backbone
Meropenem IV
2 g IV every 8 hours
CNS penetrating bactericidal agent
Linezolid IV
600 mg IV every 12 hours
Protein synthesis inhibitor reduces toxin
Clindamycin 900 mg IV every 8 hours as alternative PSI
Duration and step-down
At least 2 weeks IV
Then transition to oral
Total 60 days if aerosol exposure suspected
Covers delayed spore germination
If meningitis ruled out by LP
Two drug regimen acceptable
Fluoroquinolone plus linezolid or clindamycin
Drop the carbapenem if no CNS disease
Antimicrobial therapy cutaneous
Uncomplicated cutaneous
Oral ciprofloxacin
500 mg PO every 12 hours
7 to 10 day course
Oral doxycycline alternative
100 mg PO every 12 hours
7 to 10 day course
Extend to 60 days if aerosol exposure suspected
Bioterrorism context
Adjunctive and contraindicated therapies
Antitoxin
Raxibacumab or obiltoxaximab
Monoclonal antibodies against protective antigen
Recommended as adjunct for systemic disease
Rationale
Toxin effects continue after bacterial kill
Meningitis adjunct
Mannitol
Improved survival in meningitis patients
Reduces cerebral edema
Contraindicated agents
Extended spectrum cephalosporins
B. anthracis naturally resistant
Penicillins only if susceptibility confirmed
Under 10% natural resistance
Corticosteroids not recommended
No survival benefit and potential harm
Postexposure prophylaxis
PEP antimicrobials
Ciprofloxacin first-line
500 mg PO every 12 hours for 60 days
Doxycycline first-line
100 mg PO every 12 hours for 60 days
Levofloxacin alternative
750 mg PO every 24 hours for 60 days
Amoxicillin if penicillin susceptible
1000 mg PO every 8 hours for 60 days
PEP vaccine
Anthrax vaccine adsorbed
Doses at 0, 2, and 4 weeks
Combined with antimicrobial PEP
Special Populations
Pregnancy
Treatment priority
Anthrax is life-threatening
Effective therapy takes precedence
Ciprofloxacin remains first-line for systemic disease
Fluoroquinolone use
Benefits outweigh theoretical fetal risk in serious infection
Agent considerations
Doxycycline
Short courses acceptable when alternatives unsuitable
Weigh dental staining risk
Amoxicillin
Preferred PEP if strain penicillin susceptible
Maternal monitoring
Oxygenation goals
Maintain SpO2 >= 95% when feasible
Fetal monitoring at viable gestation
Geriatric
Atypical presentation
Blunted fever response
Infection may present without fever
Delirium as early sign
Comorbidity burden
Diabetes and COPD worsen prognosis
Medication considerations
Renal dosing adjustment
Fluoroquinolone and meropenem adjustment
Drug interaction risk
QT prolongation with fluoroquinolones
Polypharmacy review
Disposition bias
Lower threshold for admission
Frailty
Limited home supports
Pediatrics
Weight based antimicrobials
Ciprofloxacin
10 to 15 mg/kg IV every 8 to 12 hours
Maximum 400 mg per dose IV
Doxycycline
Weight based dosing acceptable for anthrax despite age
Life-threatening indication justifies use
Meropenem
40 mg/kg IV every 8 hours
Maximum 2 g per dose
PEP in children
Ciprofloxacin or doxycycline
60 day course weight based
Combined with vaccine under IND
Adherence support
Palatable formulations
Caregiver counseling
Background
Epidemiology
Disease burden and forms
Four clinical forms
Cutaneous comprises over 95% of natural cases
Inhalational, ingestion, injection
Bioterrorism classification
CDC Category A agent
Aerosol release potential
Geographic distribution
Endemic agricultural regions
Sub-Saharan Africa and central Asia
Southern and eastern Europe
Injection anthrax clusters
European heroin users
Mortality by form
Treated mortality estimates
Localized cutaneous about 2%
Systemic cutaneous about 11%
Inhalational about 45% modern era
High mortality forms
Ingestion 25 to 60%
Meningitis exceeding 90%
Pathophysiology
Organism and toxins
Bacillus anthracis
Spore-forming gram-positive rod
Spores germinate in host tissue
Tripartite toxin
Protective antigen mediates cell entry
Lethal factor and edema factor cause injury
Disease progression
Spore uptake by macrophages
Transport to regional lymph nodes
Germination and toxin release
Systemic toxemia
Vascular leak and shock
Hemorrhagic mediastinitis and meningitis
Toxin mediated nature
Toxin effects persist after sterilization
Explains death despite bacterial kill
Rationale for antitoxin
Therapeutic Considerations
Antimicrobial strategy
Combination therapy rationale
Bactericidal kill plus toxin suppression
Protein synthesis inhibitor reduces toxin output
CNS coverage
Assume meningitis until excluded
Carbapenem for CNS penetration
Countermeasures and prevention
Antitoxin availability
Strategic National Stockpile access
Adjunct in systemic disease
Vaccine role
AVA for PEP and at-risk groups
Reduces relapse after antibiotic stop
Source control
Pleural and effusion drainage
Removes toxin reservoir
Surgical debridement
Critical in injection anthrax
Patient Discharge Instructions
copy discharge instructions
Anthrax home care after treatment
Take all antibiotics exactly as prescribed
Complete the full 60 day course if instructed
Do not stop early even if you feel better
Keep all anthrax vaccine appointments if started
Why finishing antibiotics matters
Spores can stay hidden in the body
They can wake up and cause illness after stopping early
Report any new fever right away after finishing
Warning signs to return to ER
Fever, chills, or drenching sweats
Trouble breathing or chest pain
Cough or feeling much worse after seeming better
Confusion, severe headache, or stiff neck
Worsening skin sore, swelling, or black scab spreading
Severe belly pain, vomiting, or bloody diarrhea
Medication side effects
Nausea or stomach upset is common
Call your clinician rather than stopping the medicine
Report severe diarrhea promptly
Follow up
Infectious disease follow-up within 1 week
Skin lesion check in 48 to 72 hours if cutaneous
Public health may contact you for monitoring
References
Guidelines and key sources
CDC and MMWR guidance
CDC Guidelines for Prevention and Treatment of Anthrax 2023
Clinical Framework and Medical Countermeasure Use 2015
ACIP Anthrax Vaccine Recommendations 2019
Landmark reviews and consensus
Anthrax as a Biological Weapon JAMA consensus statements
NEJM Anthrax review and update
Management of Anthrax Meningitis Lancet Infectious Diseases
Evidence summaries and tools
Systematic review of hospitalized anthrax 1880 to 2018
Anthrax mass exposure triage checklist development
Overview of anthrax including injection drug use form
Coding standards
ICD-10 A22 anthrax
ICD-10 A22.1 pulmonary anthrax
SNOMED CT anthrax disorder concept
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.